Vantive, a vital organ therapy company with a 70-year legacy in kidney care innovation, announced plans to invest more than $1 billion over the next five years in expanding research and development as well as production capacity. The global investment aims to fuel innovation of digitally-enabled therapies designed to enhance care access, experience and outcomes for patients with kidney disease and other vital organ conditions.
"As we prepare to take part in our first ERA Congress as Vantive, we are proud to unveil this significant investment, which underscores our commitment to shaping the future of kidney care and vital organ support," said Chris Toth, CEO of Vantive. "Better outcomes are possible when care is more accessible, more intuitive, and more connected to the needs of patients as well as the realities of the modern healthcare ecosystem."
Addressing Growing Healthcare Burden
The investment comes as chronic kidney disease (CKD) presents an escalating global health challenge. The annual cost of CKD and end-stage renal disease (ESRD) in Europe alone is estimated to exceed €140 billion per year. As aging populations and rising rates of diabetes and hypertension drive this growing CKD patient population, the pressure on health systems is intensifying. CKD is projected to become the fifth leading cause of death globally by 2040.
Beyond chronic conditions, acute organ support therapy needs are also pressing. As many as 60 percent of patients in the intensive care unit (ICU) may have acute kidney injury. Time and resources are increasingly stretched, and clinicians urgently need smarter, scalable, and more sustainable care tools that can address more patients more effectively while keeping pace with clinical complexity.
Digital Innovation Portfolio
Vantive's investment in R&D and manufacturing capacity is intended to accelerate the pace of innovation to help healthcare systems meet this growing demand. Through the development of digitally-enabled dialysis and critical care products and services, Vantive aims to power earlier and better-informed clinical decision-making, minimize disruption of care for patients and clinical teams, shift kidney care management from episodic to proactive, and enhance patient-care team connectivity.
Remote Patient Management Platform
The Sharesource Connectivity Platform represents a cornerstone of Vantive's digital health strategy. This two-way remote patient management platform enables patients using at-home automated peritoneal dialysis (APD) to remain connected with their care teams throughout treatment, while allowing healthcare professionals to securely view and act on patients' data. Since introducing this technology 10 years ago, Sharesource has supported over 100 million home dialysis treatments for patients around the world.
For at-home APD patients, use of Sharesource has been associated with improved patient adherence to therapy as well as lower incidence of all-cause mortality, reduced hospitalization rates and reduced drop-out rates. The platform demonstrates the potential for remote monitoring technology to deliver measurable clinical benefits while supporting home-based care delivery.
Critical Care Digital Solutions
Vantive's PrisMax System represents the result of 30 years of continuous renal replacement therapy (CRRT) innovation and ICU partnership. PrisMax was developed to address the most pressing challenges of ICU healthcare practitioners in treating critically ill patients. With TrueVue Connect digital health solutions embedded, this technology provides timely data to enable CRRT management and multi-organ support in the acute setting.
Advanced Training Technologies
Vantive Learning Services provides on-demand training to support clinicians in using Vantive's therapies. This includes Vantive's VR-based educational training, which offers intensive care staff an immersive training in the use of the PrisMax System to treat patients with critical kidney injuries. The VR technology includes a virtual 3D model of the PrisMax System, preventing the need to reduce frontline service to train staff.
Company Foundation and Mission
As a new standalone company, Vantive is on a mission to extend lives and expand possibilities for patients and care teams globally. For 70 years, the company's team has driven meaningful innovations in kidney care. Today, Vantive's people, solutions and services deliver over 1 million touchpoints each day to patients around the world.
The company showcased its foundation for growth at the 62nd European Renal Association (ERA) Congress in Vienna, Austria, highlighting key products, digital solutions, advanced services and clinical studies that underscore Vantive's commitment to helping healthcare providers make better use of their limited resources while enhancing patients' freedom of choice and quality of life through equitable access to home-based therapies.
